Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Short Interest Up 37.4% in November

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) was the target of a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 20,200 shares, a growth of 37.4% from the November 15th total of 14,700 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average daily volume of 19,000 shares, the short-interest ratio is presently 1.1 days.

Cryo-Cell International Stock Performance

Shares of CCEL traded down $0.07 during trading hours on Friday, reaching $7.84. 6,563 shares of the company traded hands, compared to its average volume of 11,139. Cryo-Cell International has a 1-year low of $4.47 and a 1-year high of $9.50. The firm has a market capitalization of $63.15 million, a P/E ratio of -7.39 and a beta of 0.49.

Cryo-Cell International (NYSEAMERICAN:CCEL) last released its quarterly earnings data on Tuesday, October 15th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.11. The business had revenue of $8.07 million for the quarter. Cryo-Cell International had a negative return on equity of 42.06% and a negative net margin of 28.03%.

Cryo-Cell International Dividend Announcement

The business also recently disclosed a — dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a $0.25 dividend. The ex-dividend date was Friday, November 15th. Cryo-Cell International’s dividend payout ratio is currently -94.34%.

Institutional Trading of Cryo-Cell International

A hedge fund recently raised its stake in Cryo-Cell International stock. Geode Capital Management LLC raised its position in shares of Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) by 68.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,860 shares of the company’s stock after buying an additional 16,203 shares during the period. Geode Capital Management LLC owned about 0.49% of Cryo-Cell International worth $254,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 10.44% of the company’s stock.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.